Device repurposes cells, healing organs without additional treatment

Described in the recent issue of Nature Nanotechnology, a technology called Tissue Nanotransfection (TNT) technology has shown an ability to transform skin cells into other types of cells with 98 percent accuracy, with the potential ability to save failing organs.

A chip device is loaded with specific genetic codes or proteins and releases an electrical current when placed against the skin where it injects DNA or RNA and reprograms the cells. In lab tests on vascular veins in mice, the chip could show a change in cells at one week. By the second week, active blood vessels began to form. The legs in the mice were treated by the third week.

“It takes just a fraction of a second. You simply touch the chip to the wounded area, then remove it,” said Chandan Sen, PhD, director of the Center for Regenerative Medicine and Cell-Based Therapies at The Ohio State University Wexner Medical Center. “At that point, the cell reprogramming begins.”

In clinical tests done on the device, researchers noted it could achieve 98 percent efficiency. Researchers hope that the chip can be used on other cells than just skin cells. In tests done on the brain cells of mice, researchers were able to harvest and inject the cells back into the brain after having a stroke. In a few weeks, the brain could regain function and was healed.

“It extends the concept known as gene therapy, and it has been around for quite some time,” said study collaborator James Lee, PhD, a professor of chemical and biomolecular engineering at Ohio State. “The difference with our technology is how we deliver the DNA into the cells.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup